Type 2 Diabetes Drug Shows Promise for Type 1

Share this article:

ORLANDO—The dipeptidyl peptidase (DPP)-4 inhibitor sitagliptin, which is approved for the treatment of adult patients with type 2 diabetes, may benefit adult type 1 diabetics, investigators announced at the 70th Annual Scientific Sessions of the American Diabetes Association (ADA).

“It's important to emphasize that this was a small pilot study but nonetheless the first ever to test the use of a DPP-4 inhibitor for type 1 diabetes,” Satish Garg, MD, professor of medicine and pediatrics at the University of Colorado in Denver, commented.

For the trial, 20 inadequately controlled type 1 patients were randomized to four weeks' treatment with sitagliptin 100 mg daily or placebo and then switched to the alternate treatment for four weeks. 

Sitagliptin treatment produced a significant reduction in mean blood glucose of about 12 mg/dL, leading to a significant hemoglobin A1C reduction of 0.27%.   There was also a “near 10%” significant reduction in insulin dose during sitagliptin treatment. 

 Dr. Garg plans to follow-up his single-center pilot study with a four-month multicenter study enrolling 120 type 1 patients.

Share this article:
You must be a registered member of RUN to post a comment.

More in News

Physicians Contribute Nearly 2 Trillion in Economic Output

Physicians Contribute Nearly 2 Trillion in Economic Output

Each contributes $2.2 million in economic output, supports 13.84 jobs on average.

Clinician-to-Patient Relationship Affects Healthcare Outcomes

Clinician-to-Patient Relationship Affects Healthcare Outcomes

Meta-analysis of 13 randomized controlled trials shows small but significant effect.

NSAIDs Linked to Increased Atrial Fibrillation Risk

NSAIDs Linked to Increased Atrial Fibrillation Risk

Among elderly individuals, increased risk for current, recent use compared with never-use.